Get started
Author

Eric F. Zaniewski

Observed name: Eric Zaniewski
ORCID: 0009-0007-9309-5481
Observed ORCID: 0009-0007-9309-5481
OpenAlex ID: A5075429307
Glioblastoma extracellular vesicles modulate immune PD-L1 expression in accessory macrophages upon radiotherapy
2024 · Markus W. Schweiger, Zohreh Amoozgar, et al. · iScience · 20
The E3 ligase HECTD4 regulates COX-2-dependent tumor progression and metastasis
2025 · Joanna A. Vuille, Cem Tanriover, et al. · Proceedings of the National Academy of Sciences · 5
PDF
Modulation of Nudt21 levels reveals dose-dependent roles of alternative polyadenylation in tissue regeneration
2026 · Nikolaos Tsopoulidis, Masaki Yagi, et al. · Nature Communications · 3
CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer
2026 · Dejan Juric, Kazi N. Islam, et al. · Cancer Research · 1
Abstract 4449: SIRT5 promotes chemoresistance through metabolic rewiring for nucleotide replenishing in refractory triple negative breast cancer
2025 · Zuen Ren, Kiran Kurmi, et al. · Cancer Research · 1
Viral proteins and virus-like particles of the LTR5_Hs endogenous retrovirus in human primordial germ cell-like cells
2022 · Mutsumi Kobayashi, Misato Kobayashi, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Figure S2 from CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer
2026 · Dejan Juric, Kazi N. Islam, et al.
Data from CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer
2026 · Dejan Juric, Kazi N. Islam, et al.
Figure S1 from CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer
2026 · Dejan Juric, Kazi N. Islam, et al.
Table S2 from CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer
2026 · Dejan Juric, Kazi N. Islam, et al.
Figure S3 from CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer
2026 · Dejan Juric, Kazi N. Islam, et al.
Figure S6 from CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer
2026 · Dejan Juric, Kazi N. Islam, et al.
Table S1 from CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer
2026 · Dejan Juric, Kazi N. Islam, et al.
Figure S4 from CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer
2026 · Dejan Juric, Kazi N. Islam, et al.
Figure S5 from CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer
2026 · Dejan Juric, Kazi N. Islam, et al.
Table S3 from CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer
2026 · Dejan Juric, Kazi N. Islam, et al.
GFAP upregulation by astrocytes attenuates tau neurofibrillary tangle pathology in a mouse model of tauopathy
2026 · Clara Muñoz-Castro, Molly A. Healey, et al. · Molecular Neurodegeneration
Abstract B047: dCBP-30: A rationally designed, orally bioavailable, near-linkerless PROTAC for potent CBP/p300 degradation
2026 · Praveen Kumar. Tiwari, Bomin Ku, et al. · Clinical Cancer Research
Aberrant chromatin remodeling influences human neural cell fate change in Trisomy 21
2026 · Jenny A. Klein, Suraj Upadhya, et al. · bioRxiv (Cold Spring Harbor Laboratory)
An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma
2026 · Praveen Kumar Tiwari, Bomin Ku, et al. · Cell Reports
Abstract LB194: SIRT5 induces a metabolic switch to fuel nucleotide pools and chemoresistance in triple-negative breast cancer
2026 · Zuen Ren, Tiziano Bernasocchi, et al. · Cancer Research
A SIRT5-induced metabolic switch underlies chemoresistance and ATR checkpoint dependence in triple-negative breast cancer
2026 · Zuen Ren, Tiziano Bernasocchi, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Abstract 1781: Improving response of pancreatic cancer to losartan: Mechanistic insights and implications for personalized therapy
2026 · Heena Kumra, Ryo Morisue, et al. · Cancer Research
Abstract 372: ARNT2 and AhR promote resistance to HIF2a inhibitor belzutifan.
2026 · Dongkook Min, Sunil Poudel, et al. · Cancer Research
Abstract 257: The E3 ligase HECTD4 regulates COX-2 dependent tumor progression and metastasis
2025 · Joanna Vuille, Cem Tanriover, et al. · Cancer Research
Works count: 27
Citation count: 31
H-index: 3
I10-index: 1
Year
Topic
Type